Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Receivables - Net: 2016-2024

Historic Receivables - Net for Cytokinetics (CYTK) over the last 9 years, with Dec 2024 value amounting to $16.6 million.

  • Cytokinetics' Receivables - Net rose 640.98% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 640.98%. This contributed to the annual value of $16.6 million for FY2024, which is 1197.74% up from last year.
  • As of FY2024, Cytokinetics' Receivables - Net stood at $16.6 million, which was up 1,197.74% from $1.3 million recorded in FY2023.
  • Cytokinetics' 5-year Receivables - Net high stood at $51.8 million for FY2021, and its period low was $147,000 during FY2022.
  • Its 3-year average for Receivables - Net is $6.0 million, with a median of $1.3 million in 2023.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 99.72% in 2022, then surged by 1,197.74% in 2024.
  • Cytokinetics' Receivables - Net (Yearly) stood at $4.4 million in 2020, then soared by 1,072.38% to $51.8 million in 2021, then crashed by 99.72% to $147,000 in 2022, then soared by 772.79% to $1.3 million in 2023, then surged by 1,197.74% to $16.6 million in 2024.